Molecure stock: Molecure appoints Piotr Lutostanski. Results due October 30 concern Molecure stock

Published on 10/23/2026 at 04:27 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Molecure appointed Piotr Lutostanski on October 6, 2026. The next report is due October 30, 2026, while Molecure stock tracks clinical milestones.

Clinical progress and reporting schedule

Piotr Lutostanski joined the supervisory board on October 6, 2026.
First-half 2026 operating revenue was PLN 1.86 million, compared with PLN 3.52 million a year earlier.
The next quarterly report is scheduled for October 30, 2026.

Molecure, PLONCTH00011, Illustration mit AI erstellt.

Molecure (ISIN PLONCTH00011) appointed Piotr Lutostanski to its supervisory board on October 6, 2026, replacing Robert Oskard. The move adds a governance change to a biotech story still centered on clinical development, according to Investing.com.

Board change sets near-term test

The next scheduled report is the third-quarter 2026 report on October 30, 2026. Molecure's latest reported figures show why that date matters: operating revenue was PLN 1.86 million in the first half of 2026, down from PLN 3.52 million in the first half of 2025, while the net loss narrowed to PLN 6.31 million from PLN 8.52 million.

The company is using its cash position to advance OATD-01 and OATD-02. Cash stood at PLN 24.91 million on June 30, 2026, compared with PLN 16.35 million at the end of 2025, while operating costs fell by PLN 4.45 million year over year. These figures were reported by Molecure on September 30, 2026.

Three dated clinical milestones

In July 2026, the independent monitoring committee recommended continuing the KITE study without protocol changes after the program reached its 30-patient milestone. On September 30, 2026, Molecure said recruitment had passed 40 patients and was moving toward 50 patients for the next interim analysis. On October 6, 2026, Piotr Lutostanski joined the supervisory board after Robert Oskard resigned.

What does October 30 mean?

The report can give investors a fresh read on cash use, recruitment and the timing of the next KITE analysis. The first-half report also showed operating cash flow of minus PLN 1.39 million and financing cash flow of PLN 20.60 million, figures that separate research spending from funding activity.

Dates on the company calendar

The next reported date is October 30, 2026, for the third-quarter report. Molecure's investor calendar also lists BIO Europe in Cologne from November 9 to November 11, 2026, according to the company's investor page.

Warsaw quote and market context

Molecure was last at PLN 5.98 on the Warsaw Stock Exchange on October 22, 2026 at 4:36 p.m. CEST. The quote was below the 52-week high of PLN 9.04 and above the 52-week low of PLN 4.98, while market capitalization stood at PLN 147.8 million on the same date. The further course of trading is shown by the continuously updated real-time quote of Molecure stock.